Business context and reporting period
ReposiTrak, Inc. provides SaaS platforms for food-industry compliance, traceability, e-commerce and supply-chain management. Its hub-and-spoke model serves retailers and wholesalers and their suppliers. The filing is for the quarter ended March 31, 2024 (the company’s fiscal third quarter of 2024), not 2023 Q3 as specified in the request. It was filed May 15, 2024; the interim financial statements are unaudited.
Financial performance and position
| Metric | Three months ended March 31, 2024 | Year-over-year | Nine months ended March 31, 2024 | Year-over-year |
|---|---|---|---|---|
| Revenue | $5.085 million | +5% | $15.271 million | +7% |
| Operating income | $1.262 million | −17% | $3.703 million | −6% |
| Net income | $1.550 million | −7% | $4.380 million | +4% |
| Net income applicable to common shareholders | $1.416 million; $0.08 per basic and diluted share | Down from $1.516 million; EPS unchanged | $3.953 million; $0.22 basic, $0.21 diluted | Up from $3.774 million; EPS was $0.20 basic and diluted |
| Operating cash flow | Not separately presented for the quarter | $4.911 million | −31% | |
| Cash and cash equivalents | $24.453 million at March 31, 2024 | +2% from June 30, 2023 |
For the quarter, operating expenses rose 16% to $3.823 million, including general and administrative expense up 48% and sales and marketing up 9%. Operating margin was approximately 24.8%, versus 31.5% a year earlier; net margin was approximately 30.5%, versus 34.5%. For the nine-month period, operating margin was approximately 24.3%, versus 27.5%, while net margin was approximately 28.7%, versus 29.5%. The filing does not separately report gross profit or gross margin.
At March 31, 2024, total assets were $51.333 million, total liabilities $4.861 million, and stockholders’ equity $46.473 million. Working capital was $24.183 million and the current ratio was 6.21x. The company reported no bank debt; notes payable and financing leases were $215,274 current, with no long-term balance. Operating lease liabilities totaled approximately $278,000.
Material changes versus prior comparable periods
- Revenue growth came from recurring subscription revenue across compliance, supply-chain and traceability offerings. Recurring revenue was $5.079 million of quarterly revenue and $15.250 million of nine-month revenue.
- Profitability growth lagged revenue: quarterly operating income and net income declined, primarily as operating expenses increased. Nine-month net income rose modestly, supported in part by higher interest income.
- Nine-month operating cash flow fell $2.155 million to $4.911 million, chiefly due to higher accounts receivable and lower accounts payable. Receivables increased to $3.776 million from $2.523 million at June 30, 2023.
- Cash increased by $461,801 over the nine months. Financing activities used $4.400 million, including $1.516 million for common-stock repurchases, $1.500 million for Series B-1 preferred redemptions, and $1.287 million in dividends paid.
Outlook, commentary, risks and unusual items
- Management says cash, short-term investments and operating cash generation are expected to fund operations and investment needs for at least 12 months. It believes cash flow and working capital will continue to increase, while noting dividends and preferred-stock redemptions will use cash. No specific revenue or earnings guidance is provided.
- Management identifies food-safety and traceability requirements as a demand driver. FDA FSMA 204 compliance is due January 20, 2026; the filing also describes a large retailer’s supplier traceability requirement with a June 2025 deadline and USDA organic-enforcement requirements beginning March 2024. Adoption, timing and resulting demand remain uncertain.
- The company terminated its U.S. Bank revolving credit facility in March 2024, citing its financial position; no balance was outstanding. Management says it expects future interest income to decline if rates fall, absent taking additional credit risk.
- General and administrative expense comparisons were affected by approximately $1.175 million of net Employee Retention Credit payroll-tax refunds received in the prior fiscal year. The company also cites increased bad-debt and employee-benefit costs. Nine-month depreciation and amortization increased, partly due to security, backup, storage and redundancy upgrades; management reports approximately $420,000 spent on these upgrades.
- The board approved redemption of preferred stock for an aggregate stated purchase price of $8.964 million over three years. By March 31, 2024, 140,186 Series B-1 shares had been redeemed for $1.500 million; Series B shares remained outstanding and none had been redeemed. Preferred dividends accrue at 7% if paid in cash or 9% if paid in additional preferred shares.
- Other risks include interest-rate exposure on investments, customer collection and bad-debt risk, cybersecurity and data protection, and macroeconomic or geopolitical uncertainty. Management said these external events had not materially adversely affected results through March 31, 2024, but future effects are uncertain. No material pending or threatened legal proceeding was identified; no additional risk factors were reported beyond the prior Form 10-K.
- The company changed its name from Park City Group, Inc. to ReposiTrak, Inc. in December 2023 and moved its listing from Nasdaq to the NYSE in November 2023 (ticker TRAK). Management assessed disclosure controls as effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the period: this is fiscal Q3 2024, ended March 31, 2024, despite the request labeling it 2023 Q3.
- Track whether subscription and traceability adoption converts into sustained revenue growth, particularly ahead of the 2025 retailer and 2026 FDA deadlines.
- Monitor receivables, collections and bad-debt expense given the increase in receivables and lower operating cash flow.
- Review the remaining preferred-stock redemption schedule, preferred dividends, and common and preferred share-count effects; the filing reports $6.692 million of remaining Series B redemption amount available and $772,711 for Series B-1.
- Assess earnings quality and cost trends, including the prior-year ERC benefit, rising G&A and selling costs, and interest income’s contribution to results.